At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 20 enrolled
Drug / intervention
Pasireotide LARdrug
Likely dose
Pasireotide LAR 40 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-Label, Single Arm, Phase II Study to Evaluate the Efficacy and Safety of Pasireotide LAR on the Treatment of Patients With Clinically Non-Functioning Pituitary Adenoma
In Brief
A Phase 2 clinical trial evaluating Pasireotide LAR for Non-functioning Pituitary Adenoma. Completed, enrolled 20 participants across 7 sites.
Detailed Summary
This study assessed pasireotide LAR efficacy on patients with non-functioning pituitary adenomas concerning tumor growth.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-functioning Pituitary Adenoma
CountriesBrazil
Collaborators--
Timeline
Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedJan 2011
Enrollment StartNov 2012
Primary CompletionSep 2017
TodayJul 2026
First PostedJan 26, 2011
Enrollment StartNov 26, 2012
Primary CompletionSep 12, 2017
TodayJul 2, 2026
Enrollment to primary: 4.8 yearsPosted 15.4 years ago
Interventions
Pasireotide LARdrug
20 and 40 mg of powder in vials and 2 mL of vehicle in ampoules (for reconstitution) administered as a depot intragluteal IM (intramuscular) injection